Comparative Pharmacology
Head-to-head clinical analysis: CAPLYTA versus INVEGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPLYTA versus INVEGA.
CAPLYTA vs INVEGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors. It has no affinity for muscarinic receptors.
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
Oral: 6 mg once daily; may increase to 9 mg/day if needed. IM (extended-release): 234 mg on day 1, 156 mg on day 8, then 117 mg monthly; adjust within range 39-234 mg per month.
None Documented
None Documented
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Terminal elimination half-life is approximately 23-29 hours for oral administration (paliperidone extended-release). Once-daily dosing achieves steady-state within 4-5 days.
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Primarily renal: 59-80% of dose excreted unchanged in urine (as parent drug and metabolites). Fecal: ~20-30%. Biliary elimination is minimal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic